Search

1244447
1240861
1230819
1195994
393884
Final results from M72 AS01E TB Vaccine Trial
The final results from the M72AS01E TB vaccine study have been published in the New England Journal of Medicine. The vaccine demonstrated a 50% efficacy rate in reducing the incidence of lung TB disease in HIV-negative adults, already infected with...
Social Reponsiveness
Established in 2001, the South African Tuberculosis Vaccine Initiative (SATVI) was presented with the University of Cape Town’s (UCT) 2018 Social Responsiveness Award at the Faculty of Health Sciences graduation ceremony on Saturday, 13 April 2019
2018 Tb under the Spotlight Science Engagement
The “TB Under the Spotlight Science Engagement” programme was conceptualised and presented by South African Tuberculosis Vaccine Initiative (SATVI) with scientists from the Division of Molecular Biology and Human Genetics at Stellenbosch University...
Biomarker discovery offers hope for new TB vaccine development
A team of scientists from the University of Cape Town, Oxford University and the London School of Hygiene & Tropical Medicine have made a discovery that reveals how we can improve development of more effective vaccines against tuberculosis.
Community Engagement
Carina's Choice: SATVI collaborated with UCT Drama Department and Worcester Secondary School in developing this play which was performed by learners from Worcester Secondary School at 8 local high schools reaching approximately 8 000 adolescents in...

News

Monday, 27 January 2020
August 2019 Latest Research Published Results MTBVAC vaccine candidate offer hope for control of tuberculosis in infants

SATVI researchers have just published an article titled: "Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial" appearing in the Lancet Respiratory Medicine journal. 

Publication Date:
Tue, 13 Aug 2019 - 09:30
August 2019 Research: Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy
South African Tuberculosis Vaccine Initiative researchers Professors Mark Hatherill, Tom Scriba and Doctor Adam Penn-Nicholson have co-authored a research paper titled "Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy" appearing in the Scientific Reports journal.
Publication Date:
Fri, 02 Aug 2019 - 14:00
July 2019 Research: Multinomial modelling of TB/HIV co-infection yields a robust predictive signature and generates hypotheses about the HIV+TB+ disease state.

SATVI researcher Professor Tom Scriba has co-authored a research paper titled "Multinomial modelling of TB/HIV co-infection yields a robust predictive signature and generates hypotheses about the HIV+TB+ disease state" appearing in the PLoS One journal.

Publication Date:
Fri, 26 Jul 2019 - 15:30
July 2019 Detection of Tuberculosis recurrence, diagnosis and treatment response by a blood transcriptomic risk signature in HIV-Infected Persons on Antiretroviral Therapy.

SATVI researchers Professors Mark Hatherill, Tom Scriba, Doctors Darboe, Penn-Nicholson, Mbandi, Nicole Bilek, SImba Mabwe have authored a research paper titled "Detection of Tuberculosis recurrence, diagnosis and treatment response by a blood transcriptomic risk signature in HIV-infected persons on Antiretroviral Therapy" appearing in the Frontiers in Microbiology journal.

Publication Date:
Fri, 26 Jul 2019 - 15:15

Pages